健世科技(09877.HK)自上市低位急彈54% 自主開發Ken-Valve註冊申請進入國家藥監局優先審批程序
健世科技-B(09877.HK)自主開發的Ken-Valve註冊申請進入國家藥監局優先審批程序。該股終止十連跌,股價由上市低位反彈重越10天線(21.04元),最多飆71%高見27元,現報24.3元,飆升54%,一向稀疏成交增至51萬股,為逾五個月罕見,涉資1,128萬元。
健世科技公布,其自主開發的經導管人工主動脈瓣膜系統Ken-Valve的註冊申請,最近成功進入國家藥監局的醫療器械優先審批程序。截止日前,今年獲得國家藥監局批准進入優先審批的產品僅八款。同時,Ken-Valve亦為國家藥監局開通優先審批通道後,首個於心臟瓣膜領域獲選進入優先審批程序的產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.